Breakthrough Prize 2026: The 'Oscar of Science' Awards Muon and Therapies That Cure Blindness
On April 18, 2026, at 10 AM San Francisco time, the Breakthrough Prize Foundation announced the winners of its 14th edition — and the results reinforced a trend that has been solidifying over the past decade: life-changing science is divided between the absurdly small and the profoundly human.
On one side, three international collaborations of physicists who spent decades measuring the magnetic spin of a particle 207 times smaller than anything any human will ever see. On the other, scientists who transformed viruses into healing vehicles, restoring sight to blind children and alleviating the pain of patients with sickle cell anemia.
What Happened
The Fundamental Physics prize ($3 million) was jointly awarded to the Muon g-2 collaborations from CERN (Switzerland), Brookhaven National Laboratory (USA), and Fermilab (USA). The work involved over 200 physicists from 33 institutions across 7 countries over 25 years, culminating in the most precise measurement ever made of the anomalous magnetic moment of the muon — a value that physicists refer to as "g-2" (g minus two).
The final result, published in August 2025, confirmed a discrepancy of 5.1 sigma between the measured value and the theoretical prediction of the Standard Model — the statistical threshold that physicists consider as "discovery." Although theoretical interpretations are still under debate (with QCD lattice calculations complicating the comparison), the community recognized the experimental achievement as one of the most precise in the history of particle physics.
In the Life Sciences category, three prizes of $3 million each were awarded:
Jean Bennett and Albert Maguire (University of Pennsylvania), for the Luxturna genetic therapy for Leber Congenital Amaurosis type 2, a hereditary form of blindness.
Emmanuelle Charpentier, Jennifer Doudna, and the CRISPR team (already Nobel laureates in 2020), this time specifically for the development of the Casgevy therapy, approved in 2023, which functionally cures sickle cell anemia and beta-thalassemia using CRISPR editing.
Aaron Gitler (Stanford), for identifying the expansion of C9orf72 repeats as the main genetic cause of ALS (Amyotrophic Lateral Sclerosis) and frontotemporal dementia, affecting up to 40% of familial cases of these diseases.
Context and History
The Breakthrough Prize was created in 2012 with a declared purpose: to make science "as celebrated as sports and entertainment." With individual prizes larger than the Nobel (US$ 3 million vs. ~US$ 1 million), the foundation seeks to attract media attention to scientific achievements that would normally only be discussed at academic conferences.
The strategy has worked. The 2025 ceremony (awarding work from 2024) was watched by 4.2 million online viewers. The 2026 edition, with the inclusion of the CRISPR therapy for sickle cell anemia, is expected to attract even more attention given the direct impact on the health of millions of people — sickle cell anemia affects about 20 million people globally, with a disproportionate prevalence in sub-Saharan Africa and among Afro-descendant populations.
The muon, in turn, has held a special place in physics since the 1930s. When it was discovered in cosmic rays in 1936, physicist I. I. Rabi famously exclaimed, "Who ordered this?" — because no one had predicted its existence. Almost 90 years later, the muon continues to surprise: its measured magnetic behavior in the lab subtly differs from what theory predicts, suggesting that the Standard Model — the most successful theory in physics — may be incomplete.
Impact on the Population
| Discovery | Disease/Area | Affected People | Current Status | Impact of the Prize |
|---|---|---|---|---|
| Luxturna (RPE65) | Hereditary blindness | ~6,000 worldwide | FDA/EMA approved | Visibility for access |
| Casgevy (CRISPR) | Sickle cell anemia | ~20 million | Approved in 43 countries | Pressure for cost reduction |
| C9orf72 (ALS) | ALS + dementia | ~500,000 | In development | Acceleration of targeted therapies |
| Muon g-2 | Fundamental physics | All humanity | Interpretation phase | Legitimization of new physics |
The most immediate impact is on access to the awarded genetic therapies. Luxturna costs $425,000 per eye in the USA, and Casgevy is being marketed for $2.2 million per treatment. The visibility conferred by the Breakthrough Prize historically generates public and regulatory pressure for price reductions and expanded access — especially in low- and middle-income countries where sickle cell anemia is more prevalent.
What Those Involved Say
"It's surreal to think that we measured something 2.5 times more precisely than any measurement of quantum property ever made in history," said Professor Graziano Venanzoni, spokesperson for the Muon g-2 collaboration at Fermilab. "And that this may be telling us that there is something beyond what we know."
Dr. Jean Bennett, co-laureate for Luxturna, used her acceptance speech to advocate for equity: "This prize is not complete while all blind children in the world with this mutation do not have access to treatment. Today, less than 5% of them do."
Next Steps
The physics community is awaiting results from new theoretical QCD (Quantum Chromodynamics) calculations that may clarify whether the muon anomaly is truly "new physics" or an artifact of imperfect theoretical calculations. A definitive decision is expected by 2028.
In the field of genetic therapies, the WHO is negotiating voluntary licensing agreements for the production of Casgevy in low-income countries, a process that could reduce the cost of treatment by up to 90%.
The Future of the Standard Model
The muon anomaly has implications that go far beyond a numerical discrepancy. The Standard Model of particle physics, developed between the 1960s and 1970s, is the most precise theory ever created by humanity — its predictions have been confirmed with precision of up to 12 decimal places in some experiments. However, the model has known limitations: it does not explain dark matter (which makes up 27% of the universe), does not incorporate gravity, and does not explain why there is more matter than antimatter in the cosmos.
The discrepancy in the muon g-2 could be the first experimental signal of particles or forces beyond the Standard Model. Various theoretical extensions — including supersymmetry (SUSY), extra dimensions, and new Z' bosons — predict corrections to the muon's magnetic moment that are consistent with the observed anomaly. If confirmed, the anomaly would direct the next generation of particle accelerators in the search for these new particles.
The debate, however, is far from resolved. Theoretical calculations of g-2 using QCD (Quantum Chromodynamics) on the lattice — computational simulations of quark and gluon interactions — produced results in 2024 and 2025 that are closer to the experimental value than previous analytical calculations, potentially reducing the significance of the anomaly. The community of theoretical physicists is divided on which approach is more reliable.
Access and Equity in Genetic Therapies
The prize for genetic therapies raised crucial questions about equity in global health. Luxturna costs $425,000 per eye in the USA — a price that Spark Therapeutics (now part of Roche) justifies by decades of development and the rarity of the condition treated. Casgevy, from Vertex Pharmaceuticals, costs $2.2 million per patient.
To put it in perspective: sickle cell anemia affects approximately 20 million people globally, with over 80% of cases in sub-Saharan Africa. At current costs, treating all patients with Casgevy would cost $44 trillion — more than the global GDP. This is not feasible.
The Medicines Patent Pool (MPP), supported by the UN, is negotiating voluntary licenses with Vertex to allow generic production of Casgevy in low- and middle-income countries. Estimates suggest that production in factories in India or Brazil could reduce the cost per treatment to $50,000-100,000 — still high, but within reach of public health programs in middle-income countries.
Dr. Fyisa Berhane, an Ethiopian hematologist and advocate for access to cell therapies in Africa, commented during the Breakthrough Prize ceremony: "We celebrate a cure that 95% of the patients who need it most will never have access to. The prize is deserved, but the celebration is premature as long as the cure is a privilege, not a right."
Brazil's Role in Particle Physics
Brazil had direct participation in the Muon g-2 experiment at Fermilab through researchers from CBPF (Brazilian Center for Physics Research), USP, and UNESP, who contributed data analysis, Monte Carlo simulations, and detector instrumentation. Professor Edson Beber from UNESP in Guaratinguetá led a group that developed algorithms for reconstructing muon trajectories that improved the measurement precision by 0.3% — a contribution that the experiment's spokesperson classified as "essential for achieving the final precision." Brazil's investment in the program, through FAPESP and CNPq grants, totaled approximately R$ 4.2 million over 8 years — a tiny fraction of the total cost of the experiment ($48 million), but one that ensured the country access to data, high-impact publications, and the training of a generation of world-class experimental physicists. The award reinforces the importance of Brazil maintaining investments in international Big Science collaborations, especially at a time when budget cuts in science threaten to reduce Brazil's participation in CERN and Fermilab projects.
Closing
The Breakthrough Prize 2026 perfectly captured the duality of science in the 21st century: the pursuit of fundamental knowledge that can redefine our understanding of the universe, and the practical application that literally transforms human lives. The muon tells us that there is more in the cosmos than we know. Luxturna and Casgevy show us that what we already know may be enough to cure what was once incurable. Between the infinitely small and the profoundly human, science proves that it indeed deserves its own Oscar.
The 2026 award also serves as a reminder that fundamental science and applied science are not competitors — they are symbiotic. The muon, which I.I. Rabi asked "who ordered," may seem irrelevant to everyday life. But it is exactly this type of curiosity-driven research that has historically produced the most transformative technologies: the laser was born from pure quantum mechanics, the internet emerged from communication protocols at CERN, and proton cancer treatments were developed from particle accelerators designed to study matter.
The awarded genetic therapy for sickle cell anemia also did not emerge from nowhere — it is the result of four decades of basic research in molecular biology, genomics, virology, and immunology that had no obvious clinical application when it was funded. The Breakthrough Prize, by celebrating both the measurement of a quantum property and the cure of a genetic disease, conveys a powerful message: investing in pure science is not waste — it is sowing what future generations will reap.
The president of the Breakthrough Prize Foundation, Russian-Israeli billionaire Yuri Milner, summed it up: "The greatest discoveries of humanity began with someone asking 'why?' without knowing if the answer would have utility. Our role is to ensure that this question continues to be asked — and celebrated."
